Document:

EX-10.42

 Exhibit 10.42 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 JOINT DEVELOPMENT AGREEMENT 

 

					
	Parties:	 	SOLVAY SA, a company incorporated in Belgium with its registered office located at 33 rue du Prince Albert, B-1050 Brussels (Belgium),	  	Bioamber International S.à.r.l., a company incorporated in Luxembourg with its registered office located at 1 rue Nicolas Simmer, L-2538 Luxembourg,
			
		 	hereinafter referred to as “Solvay”	  	hereinafter referred to collectively as “Bioamber”
		
	Recitals:	 	 Solvay, as an international chemical company, is active in research and development of various technologies, products and
applications such as, but not limited to, the plasticization of polymers, and owns proprietary and valuable information related to the same.
  

Bioamber is engaged in the development, production and sales of bio-based succinic acid and salts of succinic acid, and derivatives thereof and
technologies for producing them.
  
 Solvay and Bioamber wish to collaborate
to fulfill the Purpose (as hereinafter defined).

			
	Definitions:	 		  	
		
	 “Purpose”
	 	means the development of Product according to the Program for use in the Application.
		
	 “Product”
	 	means aliphatic and/or aromatic esters of (i) bio-succinic acid, and/or (ii) its derivatives.
		
	 “Application”
	 	means the plasticization of polyvinyl chloride (PVC).
		
	 “Effective Date”
	 	means 1 October, 2011.
		
	 “JDA Term”
	 	means two (2) years from the Effective Date.
		
	 “NDA”
	 	means the Non-Disclosure Agreement entered on 1 February, 2011 between Solvay and Bioamber S.A.S., an Affiliate of Bioamber Inc.
		
	 “Secrecy Period”
	 	means the period starting on the Effective Date and ending five (5) years after the expiration, or termination for whatever cause, of this Joint Development
Agreement.
		
	 “Governing Law”
	 	means the law of France, excluding its conflicts of law principles.
		
	 “Arbitration Rules”
	 	means the Rules of Conciliation and Arbitration of the International Chamber of Commerce.
		
	“Arbitration Place”	 	means Paris (France).

 Operative provisions: 
 The parties agree to collaborate under the terms and conditions set forth hereabove and in the hereunder General Terms and Conditions. 

 

			
	    June 2011	 	Initials of parties:             

 * Confidential treatment requested 

 General Terms and Conditions 

1. ADDITIONAL DEFINITIONS 

 

	 	1.1.	In addition to the definitions given hereabove, the following capitalized terms shall have the following meanings: 

 

	 	(a)	“Affiliate” means, with respect to a party, any entity or person controlling, or controlled by, or under common control with, such party, whether
directly or indirectly; “control” (including, with correlative meanings, “controlling”, “controlled by”, and “under common control with”) meaning the power to cause the direction of the management of such
person or entity, directly or indirectly, whether through ownership of voting securities or otherwise. 

  

	 	(b)	“Background” shall mean either Background Solvay or Background Bioamber. 

 

	 	(c)	“Background Solvay” means any know-how and patent right related to the Purpose and the use of plasticizers in PVC, developed or acquired by Solvay
independently of the receipt of succinic esters from Bioamber and/or Agro-Industries Recherches et Développement (the former Bioamber joint venture partner in biobased succinic acid) both prior to and after the Effective Date, and which
Solvay is free to disclose and license without accounting to third parties, excluding the Results. 

  

	 	(d)	Background Bioamber” means any know-how and patent right related to the Purpose, the production of bio-succinic acid and/or its derivates, and the chemistry
based on such bio-succinic acid and/or derivatives, developed or acquired by Bioamber both prior to and after the Effective Date, and which Bioamber is free to disclose and license without accounting to third parties, excluding the Results.

  

	 	(e)	“Confidential Information” means (i) the existence and Purpose of this Agreement, (ii) any Background Solvay disclosed directly or indirectly
by Solvay to Bioamber under the NDA, or under this Agreement, including any material sample, (iii) any Background Bioamber disclosed directly or indirectly by Bioamber to Solvay under the NDA, or under this Agreement, including any material
sample, and (iv) any Results. 

  

	 	(f)	“Program” means the program set up by the parties for the fulfillment of the Purpose, including the tasks to be performed by each party and their
associated timing, as detailed in Appendix A hereto, and as may be amended pursuant to Sub-Clause 3.4. 

  

	 	(g)	“Result” means any data or information obtained, or any improvement or invention made, by either party, or jointly by both parties, through the
performance of the Program, but excluding any Background. 

  

	 	1.2.	The singular includes the plural and vice versa. 

 2. PURPOSE OF THE AGREEMENT 
  

	 	2.1.	The purpose of this Agreement is to define the terms which shall control the respective activities, rights and obligations of the parties with respect to the
performance of the Program, and the ownership and exploitation of the Results. 

 3. PERFORMANCE
OF THE PROGRAM 
  

	 	3.1.	Each party shall perform its tasks in accordance with the Program with the aim of having it completed within two (2) years from the Effective Date.

  

	 	3.2.	Each party shall disclose to the other party its Background as it deems necessary for the performance of the Program. 

  
 2 

* Confidential treatment requested 

	 	3.3.	Each party shall disclose to the other party the Results it obtains at regular intervals. 

 

	 	3.4.	The parties shall be entitled to jointly amend the Program, including the associated timing, as they deem appropriate. 

 

	 	3.5.	Each party shall support all costs and expenses it may incur during the performance of the Program. 

 

	 	3.6.	Solvay shall be entitled to have any of its activities hereunder performed by any of its Affiliates, including, but not limited to, by SolVin SA.

  

	 	3.7.	The parties shall explore jointly in good faith the possibility to appeal to sub-contractors that could bring esterification and/or plasticizer market expertise, such
as, but not limited to, Lanxess AG. 

 4. INTELLECTUAL PROPERTY 

Background Technology 
  

	 	4.1.	Each party shall retain full ownership of its Background. 

  

	 	4.2.	Each party shall be entitled to use the other party’s Background as disclosed pursuant to section 3.2 for the purpose of performing its tasks under the Program.

 Ownership and protection of the Results 

 

	 	4.3.	(a) The parties shall jointly own all Results and shall examine the best means to protect them. In case they elect to patent any Result, the parties shall determine the
party (the “Filing Party”) that will (i) file, in its own name, the patent application(s) embodying such Result in the relevant countries jointly agreed upon by the parties, and (ii) take all actions in connection with the
prosecution, maintenance and defense of such patent application(s), and of all patents derived therefrom. The parties shall equally share all external expense incurred for such purposes by the Filing Party. 

(b) Each party shall be entitled to file patent applications embodying Result in its name and at its expense in those countries where the
other party does not wish to file. 
 (c) Each party shall be entitled to continue, in its name and at its expense, the
prosecution, maintenance or defense of any patent right resulting from the actions taken under Sub-Clause 4.3(a) in the event the other party does not wish to continue the same. 

 

	 	4.4.	The other party shall provide assistance, do any act and execute any document, as may be requested by the Filing Party for the purpose of protecting any Results
pursuant to Sub-Clause 4.3. 

  

	 	4.5.	Each party shall be responsible for remunerating its employed inventors according to applicable inventors’ laws. 

Exploitation rights of the Results 
  

	 	4.6.	Upon successful completion of the Program and provided the Results are deemed satisfactory by both parties, the parties shall jointly decide the way to exploit jointly
such Results and shall enter into the required arrangement with the view to jointly produce and commercialize Product. 

  

	 	4.7.	In case, (i) the Results are not deemed satisfactory by either party, or (ii) despite their reasonable endeavors, the parties do not succeed in entering into a further
arrangement pursuant to Sub-Clause 4.6 within six (6) months from the completion of the Program; 

  

	 	(a)	The parties shall be free to exploit directly or indirectly any Result, and for such purpose, the Filing Party shall grant to the other party a non-exclusive and
free-of charge (subject to the patent expense sharing under Sub-Clause 4.3 (a)) license, with the right to sublicense, under any patent application filed pursuant to Sub-Clause 4.3 (a), and any patents to be granted thereof.

  

	 	(b)	Upon each party’s request, the other party shall grant to the requesting party a non-exclusive license, with the right to sublicense, under any Results claimed in
any patent right filed, prosecuted, maintained and/or defended pursuant to Sub-Clauses 4.3 (b) and/or (c), and any patents to be granted thereof, subject to the reimbursement by the requesting party of half of the external expense (to be) incurred
by the other party in connection with such filing, prosecution, maintenance and/or defense. 

  

	 	(c)	Upon either party’s request, the other party shall negotiate in good faith fair and reasonable terms and conditions for the grant of a non-exclusive license under
its Background as necessary for the exploitation of the Results by the requesting party, it being understood that Bioamber shall not be under no obligation to license to Solvay its proprietary technology for the production of biobased succinic acid.

 5. REPRESENTATION, WARRANTIES AND
RESPONSIBILITIES 
  

	 	5.1.	Representation. Each party represents and warrants that it has the right to enter into this Agreement and to fulfill its obligations hereunder, and that it is
under no contract or agreement, and will not enter into any contract or agreement during or after the term of this Agreement that will prevent it from performing its duties and obligations under this Agreement. 

  
 3 

* Confidential treatment requested 

	 	5.2.	Disclaimer of warranties. Neither party makes any warranties, express, implied, statutory or otherwise, concerning any information, results or materials provided
to the other party under this Agreement. In particular, any and all warranties, including, but not limited to, any warranty of merchantability, non-infringement of third party intellectual property rights, fitness for a particular purpose, and any
other warranty arising from the course of performance; course of dealing or usage in the trade of the same, are hereby disclaimed. 

  

	 	5.3.	Limitation of liability. Except in case of gross negligence, willful misconduct, or fraudulent misrepresentation, neither party nor its employees shall be liable
to the other party for any loss, damage, costs or expenses of any nature whatsoever incurred or suffered of an indirect, incidental or consequential nature, including any economic loss or other loss of turnover, loss of profits, business or goodwill
arising out of the performance of the Program, the use of any Background or Result, and/or the handling, use or disposal of any material sample, apparatus, equipment, method or process. 

 

	 	5.4.	Indemnification for bodily injury. Each party shall indemnify the other party, its Affiliates and subcontractors for any damages any representative of any of the
foregoing may suffer as result of personal bodily injury, including death, or property damage or loss which may occur while such representative is performing any activity under this Agreement in the premises of the indemnifying party and which is
due to the negligence or willful misconduct of the indemnifying party, or its Affiliates, or employees or subcontractors of any of the foregoing. 

 6. CONFIDENTIALITY AND PUBLICATION 
  

	 	6.1.	Obligations. With respect to Confidential Information, the receiving party shall: 

(a) use the same degree of care as it uses for protecting its own confidential information of a like nature (but in no event less than a
reasonable degree of care), including, by keeping the same in tangible or documented form, in secure storage and reasonably separate from other information, 
 (b) not disclose the same to any third party except to its Affiliates, or as authorized under this Agreement, 
 (c) not use the same for any purpose other than as explicitly permitted under this Agreement, 
 (d) limit access to the same, on a strict need to know basis, to its and its Affiliates’ employees, requiring that access to perform the Program and/or exploit the receiving party’s rights
hereunder, provided such employees are subject to confidentiality obligations through appropriate agreements, have been informed by the receiving party of the obligations hereunder, and the receiving party remains responsible for any violation of
the obligations hereunder by such employees; 
 (e) not disassemble, analyze, or have others analyze, Confidential Information
(except Results) in the form of material samples to determine the chemical composition, microscopic structure or method of manufacture of such samples, except to the extent strictly required to fulfill the Purpose, and 

(f) upon request and option of the disclosing party, either return Confidential Information (except Results), including copies, extracts
and notes of the same, and material samples, to the disclosing party, or destroy (or delete permanently in the case of digital or electronic media) the same, except that the receiving party may retain one (1) copy of such Confidential
Information in limited access files in accordance with the terms of this Agreement for the sole purpose of determining its legal obligations hereunder with respect to such Confidential Information, and that this obligation shall not apply to
routinely created backup copies of electronic data. 
  

	 	6.2.	Exceptions. The obligations of Sub-Clause 6.1 shall not apply to any portion of Confidential Information that the receiving party can prove:

 (a) was available to the public prior to receipt or achievement hereunder, or becomes available to the public
thereafter through no fault or negligence of the receiving party, or 

  
 4 

* Confidential treatment requested 

 (b) was already in the receiving party’s possession and was obtained from a source
other than the disclosing party or any of its Affiliate prior to receipt or achievement hereunder, or 
 (c) was lawfully
obtained from a third party legally entitled to do so after the time of receipt or achievement hereunder, and the receiving party is free to disclose without breach of any of its obligations, or 

(d) was independently developed by or for the receiving party without using Confidential Information. 

For the purpose of this Article, any information which is specific, shall not be deemed to be within any of the foregoing exceptions,
merely because it is embraced by more general information which falls within any one or more of the foregoing exceptions. In addition, any combination of features shall not be deemed to be within any of the foregoing exceptions, merely because
individual features fall within any one or more of the foregoing exceptions, but only if the combination itself falls within any one of the foregoing exceptions. 
  

	 	6.3.	Disclosure upon process. In the event the receiving party is required to disclose Confidential Information under applicable law, regulation, supervisory
authority or other applicable judicial or governmental order, the receiving party shall (i) inform the disclosing party in writing before any disclosure thereof so that the disclosing party may seek an appropriate protective order,
(ii) give upon the disclosing party’s request all necessary information and support to ward off the disclosure thereof, (iii) ask the receiving third party to maintain confidentiality, and (iv) strictly limit the content of such
disclosure to that portion of Confidential Information that it is strictly compelled to disclose. In any event, the receiving party shall not oppose action by the disclosing party to obtain an appropriate protective order or other reliable assurance
that confidential treatment will be accorded to Confidential Information. 

  

	 	6.4.	Disclosure to consultants and sub-contractors. The receiving party shall be entitled to disclose Confidential Information to its consultants and sub-contractors,
provided (i) such disclosure is required for the performance of the Program and/or the exploitation of the receiving party’s rights hereunder, (ii) such consultants and sub-contractors have been informed by the receiving party of the
obligations hereunder, and (iii) the receiving party remains responsible for any violation of the obligations hereunder by such consultants and sub-contractors. 

 

	 	6.5.	Publication. Either party shall not make any use of the name of the other party, or of any of its Affiliates, in connection with this Agreement in any technical,
advertising, promotional or sales literature without the prior written consent of the other party, with the exception of publications required for, or resulting from, the filing of patent applications as provided hereunder. 

7. TERM AND TERMINATION 

 

	 	7.1.	Term. This Agreement shall enter into force as of the Effective Date, and unless terminated pursuant to Sub-Clause 7.2 or 7.3, shall remain in full force and
effect until the completion of the Program, or the JDA Term, whichever occurs first. 

  

	 	7.2.	Termination for breach or bankruptcy. Each party shall have the right, but shall be under no obligation, to terminate this Agreement if the other party:

 (a) is shown to be in breach or default in the performance of any of its obligations or covenants hereunder and
fails to remedy the same within sixty (60) days of a written notice to do so; 
 (b) ceases to do business; or 

  
 5 

* Confidential treatment requested 

 (c) is adjudged a bankrupt or has its assets placed in the hands of a receiver or make any
assignment or other accommodation for the benefit of creditors or files or has filed against it a petition for reorganization. 
  

	 	7.3.	Termination for convenience. Each party shall have the right to terminate this Agreement at any time if the Results so-far obtained are not satisfactory.

  

	 	7.4.	Survival. The provisions of Clauses 4 and 5, and of Sub-Clauses 6.5, 8.1 and 8.2, shall survive the expiration, or termination for any cause, of this Agreement.
The provisions of Sub-Clauses 6.1 to 6.4 shall survive the expiration, or termination for any cause, of this Agreement during the Secrecy Period. 

 8. MISCELLANEOUS 
  

	 	8.1.	Applicable Law. This Agreement shall be governed by and construed in accordance with the Governing Law. 

 

	 	8.2.	Arbitration. All disputes arising out of, or in connection with, the interpretation, performance and/or termination of this Agreement, which cannot be amicably
settled between the parties, shall be finally settled under the Arbitration Rules by one or more arbitrators appointed in accordance with such Arbitration Rules. Arbitration proceedings shall take place in the Arbitration Place, and shall be
conducted in the English language. The award rendered therein shall be final and binding upon the parties. The foregoing is without prejudice to each party’s right to seek injunctions and other relief in any appropriate court, to the extent
such relief is not available in arbitration. 

  

	 	8.3.	Clauses and Headings. Unless the context otherwise indicates, references to Clauses, Sub-Clauses and Appendices are to Clauses and Sub-Clauses of, and Appendices
to, this Agreement. Headings to Clauses and Sub-Clauses in this Agreement are included for the purpose of ease of reference only and shall not have any effect on the construction or the interpretation of this Agreement. 

 

	 	8.4.	Entire Agreement. This Agreement, as may be amended pursuant to the provisions hereof, constitutes the entire understanding between the parties in connection
with the Purpose, and supersedes any agreements, communications, understandings, promises, or any other arrangement, whether written or oral, made or existing between the parties prior to or simultaneously with this Agreement in connection with the
Purpose. For the sake of clarity, from and after the Effective Date, the NDA will remain in effect, other than as it applies to the Purpose, such that (i) any Confidential Information disclosed by one party to the other from and after the
Effective Date in connection with the Purpose will be subject to the confidentiality provisions of this Agreement, and (ii) any Confidential Information disclosed by one party to the other that is not in connection with the Purpose will remain
subject to the NDA. 

  

	 	8.5.	Export Regulation. Each party agrees to comply with all applicable export control laws and regulations, including the requirement for obtaining any export
license or agreement, if applicable. Without limiting the foregoing, each party agrees that it will not transfer any export controlled item, information, data, or technology, generated or received in connection with the Purpose, to foreign persons
employed by, associated with, or under contract to, such party in violation of applicable regulations. 

  

	 	8.6.	Force Majeure. If either party is prevented from or delayed in carrying out any of the provisions of this Agreement by reason of any acts of God, war, labor
disturbances, lack or failure of transportation facilities, sources of supply of labor, raw materials, power or supplies, or by reason of any law, order, proclamation, regulation, ordinance, demand or requirement of any Government or any
subdivision, authority or representatives of any such Government, or by reason of any other cause whatsoever beyond the reasonable control of such party, preventing or delaying the performance of its obligations hereunder, the party so prevented in
or delayed shall be excused from such performance to the extent and during the period of such prevention or delay, without, however, extending the term of this Agreement. 

  
 6 

* Confidential treatment requested 

	 	8.7.	Further agreement. Except as expressly set forth hereunder, nothing herein shall be deemed to provide a commitment by either party to enter into any further
agreement with the other party. 

  

	 	8.8.	Independence of the parties. Nothing in this Agreement shall grant to either party the right to make commitments of any kind for, or on behalf of, the other
party. This Agreement is not intended to be, nor shall it be construed as, a joint venture, teaming relationship, partnership, or other formal business arrangement. 

 

	 	8.9.	No assignability. Either party shall not, without prior written consent of the other party, assign this Agreement or any right or obligation hereunder, in whole
or in part, without prior written consent of the other party, except that the parties shall be entitled to assign this Agreement and/or such rights and obligations, to any of their respective Affiliates, and/or to any third party acquiring all or
substantially all assets of the business to which this Agreement relates, provided that such Affiliate and/or third party agree in writing to be bound by the terms of this Agreement. 

 

	 	8.10.	Notice. Any notice provided for in this Agreement, shall be in the English language and shall be served by registered mail, postage prepaid and shall be
therefore effective from the fifth day after the date of mailing. 

 Notices to Solvay shall be addressed to :

 SOLVAY SA 
 Attention: Philippe Meyrant 
 Rue de Ransbeek, 310

 B-1120 Brussels, Belgium 
 With a copy to : 
 SOLVAY SA 

Attention: Intellectual Assets Management Department 

Rue de Ransbeek, 310 
 B-1120 Brussels, Belgium 
 Notices to Bioamber shall be addressed to :

 Attention: Jean-François Huc 

1, rue Nicolas Simmer 
 L-2538 Luxembourg 
 With a copy to : 

Boivin Desbiens Senécal, s.e.n.c. 

Attention: Thomas Desbiens 

2000 McGill College, Suite 2000 
 Montréal, Québec, Canada 
 H3A 3H3 

 

	 	8.11.	No variation. No variation of this Agreement shall be effective unless it is in writing signed by a duly authorized representative of each party.

  

	 	8.12.	Severability. In case any one of the provisions contained in this Agreement should be invalid, illegal or unenforceable in any respect in any jurisdiction, the
validity, legality and enforceability of such provision or provisions shall not in any way be affected or impaired thereby in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein and
therein shall not in any way be otherwise affected or impaired thereby. 

  

	 	8.13.	Waiver. No waiver by either party of any provision of this Agreement shall constitute a waiver of any other provision nor shall any waiver constitute a
continuing waiver. 

  
 7 

* Confidential treatment requested 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives in two (2) original copies, each party acknowledging having received its own copy. 
  

									
	SOLVAY SA	 		 	BIOAMBER INTERNATIONAL S.à.r.l.
			
	/s/ Jean-François Serrier	 		 	/s/ J.F. Huc
					
	    Name:	 	Jean-François Serrier	 		 	    Name:	 	 J.F. Huc

					
	    Title:	 	 Senior Executive Vice President
 General Manager
 Intellectual Assets Management
	 		 	    Title:	 	 President

		 	 		 	    Name:	 	  

		 	 		 	    Title:	 	  

  
 8 

* Confidential treatment requested 

 Appendix: 
 Appendix A: General Outline Of Respective Tasks 
 BioAmber 

 

	 	•	 	 Identification and sourcing of [***] 

  

	 	•	 	 [***] assessment of potential Products 

  

	 	•	 	 Production of [***] 

  

	 	•	 	 Characterization of the Products, including [***] 

 Solvay 
  

	 	•	 	 Identification of potentially [***] 

  

	 	•	 	 [***] of various Products 

  

	 	•	 	 [***] of potential Products 

While each party will have specific responsibilities, the joint development program will be executed in close coordination between the parties and all
results and milestones will be shared in a regular manner. 

  
 9 

* Confidential treatment requestedEX-10.44

 Exhibit 10.44 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 SUPPLY AGREEMENT 

ENTERED AS OF JULY 1, 2011 (THE “EFFECTIVE DATE”). 
  

			
	BETWEEN:	  	BIOAMBER S.A.S., a French “Société par Actions Simplifiée”, having a corporate office located at 1250, Rene-Levesque West, Suite 4110,
Montreal, Quebec, Canada, H3B 4W8;
		
		  	(hereinafter referred to as “BioAmber”)
		
	AND:	  	Mitsubishi Chemical Corporation , a Japanese entity duly existing and having its principal place of business located at 14-1, Shiba 4-Chome, Minato-ku, Tokyo 108-0014,
Japan;
		
		  	(hereinafter referred to as “MCC”)

 Whereas, BioAmber is inter alia engaged in the development, production and sales of bio-based succinic acid (the
“Product(s)”); 
 Whereas, pursuant to a Memorandum of Understanding dated as of March 7, 2011
entered into between BioAmber Inc., Mitsui & Co., Ltd. (“Mitsui”) and MCC, BioAmber Inc. has agreed to make its best efforts to conclude this Agreement with MCC, by July 1st, 2011; 
 Whereas MCC and PTT Public Company Limited (“PTT”), a Thai state-owned SET-listed oil and gas company, have established PTT MCC Biochem Company Limited (“PTT MCC”) as a
joint venture in the field of PBS products; 
 Whereas BioAmber secured a source of bio-based succinic acid in a 2,000MT production plant
located in Route de Bazancourt – 51100 REIMS, France (the “Demo Plant”); 
 Whereas BioAmber and Mitsui have entered into a
distribution agreement (the “Mitsui Distribution Agreement”) pursuant to which BioAmber has appointed Mitsui as its exclusive distributor in Asia for Products produced at the Demo Plant; 

Whereas BioAmber is going to build a large-scale production plant for the Products located in Sarnia, Canada (the “Commercial Plant”);

 Whereas BioAmber is willing to supply Products to MCC according to the terms of this Agreement; 

Whereas MCC wishes to source the Products exclusively from BioAmber, subject to the terms of this Agreement; 

THEREFORE, THE PARTIES AGREE AS FOLLOWS: 
  

	1.	Term and Commitments 

  

	 	1.1	 This Agreement shall be in force from the Effective Date (as this term is defined in the preamble of this Agreement) and for a period of five (5) years
thereafter. In the event that MCC transfers its business of PBS products to PTT MCC, then this Agreement shall be assigned from MCC to PTT MCC so that PTT MCC becomes a party to this Agreement having rights and obligations identical to those of MCC
under this Agreement, and shall be 

  
 1 

* Confidential treatment requested 

	 	
subsequently terminated with respect to PTT MCC, upon the commencement of commercial operation of PTT MCC’s own manufacturing facilities for PBS products, provided the Supply Agreement
attached hereto as Schedule A enters into force concurrently. 

  

	 	1.2	Notwithstanding the preceding, either party shall be entitled to terminate this Agreement prior to its expiry date upon the occurrence of any default or omission of the
other party to fulfill any of its material obligations under this Agreement, on the thirtieth calendar day following the sending of a written notice to such defaulting party indicating any such default or omission, unless such defaulting party has
remedied said default or omission, within the said 30 days. 

  

	 	1.3	During the term of this Agreement, MCC shall, on its own account and on behalf of its affiliates (as defined in subsection 1.4 below): 

 

	 	i.	cooperate with BioAmber to assess the market potential of the Products; 

  

	 	ii.	update its purchasing forecast every three months; and 

  

	 	iii.	purchase, whether directly or indirectly, the Products exclusively from BioAmber, to meet all the Products requirements of MCC and its affiliates (as defined in
subsection 1.5 below), unless BioAmber does not have the capability to fulfill MCC’s volume requirement. 

  

	 	1.4	During the term of this Agreement, BioAmber shall, on its own account and on behalf of its affiliates: 

 

	 	i.	cooperate with MCC to assess the market potential of the Products; 

  

	 	ii.	update its production plan in accordance with the purchase forecast to be provided by MCC; and 

 

	 	iii.	supply, whether directly or indirectly, the Products to meet all requirements of the Products to MCC, in priority to other customers of BioAmber.

  

	 	1.5	For the purpose of this Agreement, an affiliate of MCC shall mean any corporation, firm, limited liability, partnership or other entity that directly or indirectly
controls or is controlled by or is under common control with MCC. For the purpose of this definition, control means ownership, directly or through one or more affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote
for the election of directors in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, or status as a general partner in any partnership, or any other arrangement
whereby an ability to appoint fifty percent (50%) or more of the members of or the board of directors or equivalent governing body of a corporation or other entity is owned. 

 

	 	1.6	MCC’s current non-binding purchase requirement of Products for the following years are as follows: 

[***] 
  

	 	1.7	MCC shall issue its binding written purchasing orders for any purchase of Product according to this Agreement at least 45 days before the requested delivery date (a
“Purchase Order”). Each Purchase Order shall be at least five hundred kilograms (500 kg) of Product. 

  
 2 

* Confidential treatment requested 

	 	1.8	BioAmber shall confirm and approve or refuse to approve each Purchase Order in writing within 10 days of receipt (BioAmber may refuse to approve a Purchase Order only
if it does not have the capability to fulfill MCC’s volume requirement, [***]). BioAmber shall deploy commercially reasonable efforts to produce and deliver the ordered Products as per MCC’s Purchase Orders. 

 

	 	1.9	BioAmber shall produce and deliver the Products according to the specifications described in Exhibit A attached hereto, which forms an integral part hereof (the
“Product Specifications”). Delivery shall take place through BioAmber’s distributor Mitsui. Such Product Specifications are subject to change from time to time provided both parties agree to the changes in advance, acting reasonably,
and the actual Product Specifications will be delivered and remitted to MCC together with each Product delivery, in the form of a certificate of analysis. 

  

	 	1.10	BioAmber shall assist MCC in all its reasonable commercial or technical questions related to the Product. BioAmber shall provide MCC with samples and brochures related
to the Product as reasonably requested by MCC. 

  

	 	1.11	During the term of this Agreement and thereafter, MCC shall not resell the Products to any other person, firm or entity, it being understood that internal assignment of
Products to an affiliate of MCC (as defined in subsection 1.4 hereof) shall not be deemed to be a resale of Products for the purpose of this Agreement. 

  

	 	1.12	All Parties shall keep adequate records in sufficient detail to allow the other Parties (“Auditing Party”) to audit the compliance of undertakings by each
Party (“Audited Party”) hereunder . Auditing Party shall have the right, upon fifteen (15) days prior notice to Audited Party, to audit during regular business hours, those records deemed by the Auditing Party to be reasonably
necessary to audit the compliance by Audited Party of its undertakings under this Agreement. During such examination, the Auditing Party has a right to examine any and all relevant documents including without limitation those records required to be
maintained pursuant to Section 1.11. If any such audit reveals that Audited Party has not complied with its undertakings provided under this Agreement, then, without limiting any other rights Auditing Party may have, Audited Party shall
immediately (i) reimburse Auditing Party’s expenses incurred in conducting the audit, and (ii) pay to Auditing Party an amount equal to the number of kilos by which it failed to meet its obligation under subsection 1.3 iii) or 1.4
iii), as the case may be, multiplied by the then applicable price per kg as per subsection 2.1 hereof. 

  

	 	1.13	Notwithstanding any other provision of this Agreement, MCC acknowledges and accepts that (i) so long as the Mitsui Distribution Agreement is in force, all Products
produced at the Demo Plant to be purchased by MCC hereunder shall first be sold by BioAmber to Mitsui, which shall in turn sell such Products to MCC upon the terms and conditions set out in this Agreement and (ii) BioAmber may, in its
discretion, appoint a distributor for Products produced at the Commercial Plant and, in such event, all Products produced at the Commercial Plant to be purchased by MCC hereunder shall first be sold by BioAmber to such distributor, which shall in
turn sell such Products to MCC upon the terms and conditions set out in this Agreement. 

  

	2.	Price, Incoterms (2010), Packaging and Payment Terms 

  

	 	2.1	For the Product produced at the Demo Plant, MCC shall pay BioAmber [***] of Product ordered pursuant to a Purchase Order duly approved by BioAmber.

  
 3 

* Confidential treatment requested 

 For the Product produced at the Commercial Plant, MCC shall pay BioAmber [***] of Product
ordered pursuant to a Purchase Order duly approved by BioAmber, it being understood that such price of [***] is based on the fact that the price paid by BioAmber for the corn used as raw material for the manufacture of the Products is of [***], as
established by the Chicago Board of Trade (CBOT). Should the price of corn deviate by more than 10% from this basis, the parties will renegotiate in good faith to adjust downwards or upwards the price of the Products. The monthly average price of
corn on the CBOT shall be used as the basis for future price adjustments. 
 In order (i) to maintain its competitive advantage,
and (ii) to allow MCC to increase the quantity of Product to be purchased pursuant to this Agreement, BioAmber may, without being obliged to do so, reduce the abovementioned prices as (a) improvements are made to the BioAmber technology operating in
the Demo Plant, and (b) cost reductions are achieved through any technology development between BioAmber and MCC, including but not limited to the use of MCC’s proprietary corynebacterium strain. Such price adjustments shall be negotiated in
good faith between the parties. 
 In any event, MCC shall not pay [***] than equivalent quality bio-based succinic acid
available from third parties, and notwithstanding anything to the contrary herein, MCC shall be free to source from third parties any portion of its needs that cannot be supplied by BioAmber. Neither BioAmber nor Mitsui (as distributor of the
Products) will be liable for any portion of MCC’s bio-based succinic acid needs that BioAmber and Mitsui fail to supply. 
  

	 	2.2	Payment shall be made electronically by MCC to BioAmber’s bank account within thirty (30) days after invoice date. MCC agrees to pay a monthly interest charge
on overdue amounts for Products purchased hereunder calculated on the basis of an annual rate of interest equal to 12%. 

  

	 	2.3	BioAmber shall deliver the Products (CIF Japanese port - Incoterms 2010) in 500 kg big-bags that will be transported and labelled in accordance with international
regulations. BioAmber shall deliver the goods with all necessary shipping documents. 

  

	 	2.4	Risk in the Products and title to the Products shall pass from BioAmber to MCC pursuant to the Incoterms mentioned in 2.3 above. 

 

	3.	Confidentiality 

  

	 	3.1	In connection with this Agreement, it is acknowledged that either party (a “disclosing party”) may disclose its Confidential Information to the other party (a
“receiving party”). For the purposes of this Agreement “Confidential Information” shall mean all information in the broadest sense in whatever form or medium that relates to past, present, or future research, development,
manufacture and sale of the products of the disclosing party, and will include, but not be limited to, this Agreement and its terms. 

  

	 	3.2	The receiving party shall maintain the Confidential Information of the disclosing party in confidence, and shall not disclose or otherwise communicate such Confidential
Information to others, or use it for any purpose except pursuant to, and in order to carry out, the terms and objectives of this Agreement, and hereby agrees to exercise every reasonable precaution to prevent and restrain the unauthorized disclosure
of such Confidential Information by any of its directors, officers, employees, consultants or agents. 

  

	 	3.3	The confidentiality obligations and use restrictions provided herein will be valid during the term of this Agreement and for an additional ten (10) years thereafter.

  
 4 

* Confidential treatment requested 

	 	3.4	The confidentiality obligations and use restrictions provided herein shall not apply to any Confidential Information which – as the receiving party can prove by
written instrument – (i) was in the lawful possession of the receiving party prior to the disclosure thereof by the disclosing party or, (ii) is or becomes generally available to the public through no act or failure to act of the
receiving party or, (iii) is given to the receiving party by a third party which is under no direct or indirect confidentiality obligation to the disclosing party or, (iv) is developed independently by employees of the receiving party who
had no access to Confidential Information disclosed hereunder. 

  

	 	3.5	BioAmber and MCC agree that no public announcement of this Agreement shall be made by either party without the prior written approval of the other party, unless
required by law or the SEC. 

  

	 	3.6	Notwithstanding the preceding, BioAmber shall be free to disclose the terms of this Agreement (explicitly excluding any and all technical and marketing information of
MCC) to its shareholders or prospective investors under a relevant confidentiality agreement with such shareholders or prospective investors without prior written approval from MCC. 

 

	4.	Representations and Warranties 

  

	 	4.1	MCC and BioAmber warrant that they have the necessary power to conclude this Agreement. 

 

	 	4.2	BioAmber warrants that it has secured the right to use the Demo Plant until December 31, 2014, while it is expected that the manufacture of Products will be made
from the Commercial Plant before that date. 

  

	 	4.3	BioAmber warrants that the Products that will be produced from the Commercial Plant will be at least of a quality comparable to the Products produced from the Demo
Plant. 

  

	 	4.4	BioAmber warrants that it has the full intellectual property rights to produce and sell the Products to MCC according to the terms hereof. 

 

	 	4.5	BioAmber warrants to MCC that the Products shall, for a period of one (1) year from their respective date of production, correspond with the Product Specifications
attached hereto as Exhibit A or then applicable. This warranty does not cover defects resulting from (i) use that is non-compliant with the reasonable, written instructions of BioAmber, (ii) improper use, improper storage or improper
handling after the Products have been delivered, or (iii) any modification or transformation of the Products that has not been approved by BioAmber. 

  

	 	4.6	BioAmber shall vest in MCC good and valid title to the Products sold and paid, which shall be free and clear of all liens, security interests, encumbrances, burdens and
other claims. No express and no implied warranties whether of merchantability or fitness for any particular use, or otherwise other than those expressly set forth in this Agreement which are made expressly in lieu of all other warranties shall apply
to the Products sold to MCC, and no waiver, alteration, or modification of the foregoing conditions shall be valid unless made in writing and signed by BioAmber and MCC. 

 

	 	4.7	IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, PUNITIVE OR EXEMPLARY DAMAGES, HOWEVER CAUSED, INCLUDING, BUT
NOT LIMITED TO, LOST INCOME OR LOST REVENUE, WHETHER FOR BREACH OF WARRANTY, CONTRACT, TORT NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 5 

* Confidential treatment requested 

	 	4.8	Without prejudice to any other remedies under the applicable laws, if any Products sold under this Agreement are not supplied in compliance with the warranties set out
in Section 4 hereof, MCC shall be entitled (i) to require BioAmber to repair the Products or to supply replacement Products in accordance with this Agreement within thirty (30) days; or (ii) at MCC’s sole discretion, to
terminate the relevant Purchase Order and require the repayment of the price which has been paid by MCC to BioAmber for the Products in question. 

  

	 	4.9	Notwithstanding the generality of the provisions set out in Section 4.8, BioAmber shall indemnify and hold harmless MCC, its Affiliates, directors, officers,
employees and agents from and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses (including reasonable attorney’s fees) in connection with any suit, demand or action by any third party
(“Losses”) arising out of or resulting from (A) any actual breach of its representations, warranties or obligations under this Agreement; (B) any negligence or willful misconduct by BioAmber, except to the extent that any of the
foregoing arises out of or results from the actual negligence, willful misconduct or breach of this Agreement by MCC; or (C) any actual infringement or violation of any patent, trade secret, copyright, trademark or other proprietary rights by
BioAmber in the manufacture of the Products pursuant to this Agreement. 

  

	 	4.10	MCC warrants to BioAmber that (i) MCC specifically assumes the liability and responsibility related to the use of the Products sold pursuant to this Agreement, and
(ii) MCC’s importation, packaging, storage, transportation, labelling, marketing, and all other activities related to the Products sold pursuant to this Agreement shall conform in all respects to present and future laws, rulings, rules,
standards, and regulations related to the Products by the applicable authorities. 

  

	 	4.11	MCC shall indemnify and hold harmless BioAmber, its Affiliates, directors, officers employees and agents from and against all Losses arising out of or resulting from
(A) any breach of its representations, warranties or obligations under this Agreement; (B) any negligence or willful misconduct by MCC, except to the extent that any of the foregoing arises out of or results from the actual negligence,
willful misconduct or breach of this Agreement by BioAmber. 

  

	 	4.12	 All indemnification obligations in this Agreement are conditioned upon the party seeking indemnification (the “Indemnified Party”):
(A) promptly notifying the indemnifying party (the “Indemnifying Party”) of any claim or liability of which the Indemnified Party becomes aware (including a copy of any related complaint, summons, notice or other instrument),
provided, however, that failure to provide such notice within a reasonable period of time shall not relieve the Indemnifying Party of any of its obligations hereunder except to the extent the Indemnifying Party is materially prejudiced by such
failure; (B) cooperating with the Indemnifying Party in the defense of any such claim or liability (at the Indemnifying Party’s expense), and (C) not compromising or settling any claim or liability without prior written consent of the
Indemnifying Party. The liability of an Indemnifying Party under this section 4 with respect to Losses arising from claims of any third party which are subject to the indemnification provided for in this section 4 (“Third Party
Claims”) shall be governed by and contingent upon the following additional terms and conditions. If an Indemnified Party shall receive notice of any Third Party Claim, the Indemnified Party shall give the Indemnifying Party notice of such
Third Party Claim within thirty (30) days of the receipt by the Indemnified Party of such notice; provided, however, that the failure to provide such notice shall not release the Indemnifying Party from any of its obligations
under this section 4 except to the extent the Indemnifying Party is materially prejudiced by such failure. The Indemnifying Party shall be entitled to assume and control the defense of such Third Party

  
 6 

* Confidential treatment requested 

	 	
Claim at its expense and through counsel of its choice if it gives notice of its intention to do so to the Indemnified Party within thirty (30) days of the receipt of such notice from the
Indemnified Party; provided, however, that if there exists a material conflict of interest that would make it inappropriate for the same counsel to represent both the Indemnified Party and the Indemnifying Party, then the Indemnified
Party shall be entitled to retain its own counsel, at the expense of the Indemnifying Party, provided that the Indemnifying Party shall not be obligated to pay the reasonable fees and expenses of more than one separate counsel for all Indemnified
Parties, taken together. In the event the Indemnifying Party exercises the right to undertake any such defense against any such Third Party Claim as provided above, the Indemnified Party shall cooperate with the Indemnifying Party in such defense
and make available to the Indemnifying Party, all witnesses, pertinent records, materials and information in the Indemnified Party’s possession or under the Indemnified Party’s control relating thereto as is reasonably required by the
Indemnifying Party. Similarly, in the event the Indemnified Party is, directly or indirectly, conducting the defense against any such Third Party Claim, the Indemnifying Party shall cooperate with the Indemnified Party in such defense and make
available to the Indemnified Party, all such witnesses, records, materials and information in the Indemnifying Party’s possession or under the Indemnifying Party’s control relating thereto as is reasonably required by the Indemnified
Party. The Indemnifying Party shall not, without the written consent of the Indemnified Party (which shall not be unreasonably withheld or delayed), (a) settle or compromise any Third Party Claim or consent to the entry of any judgment which
does not include as an unconditional term thereof the delivery by the claimant or plaintiff to the Indemnified Party of a written release from all liability in respect of such Third Party Claim or (b) settle or compromise any Third Party Claim
if the settlement imposes equitable remedies or material obligations on the Indemnified Party other than financial obligations for which such Indemnified Party will be indemnified hereunder and which contains no admission of fault or wrongdoing. No
Third Party Claim shall be settled or compromised by the Indemnified Party without the written consent of the Indemnifying Party (which shall not be unreasonably withheld or delayed) if such settlement or compromise would result in an obligation of
the Indemnifying Party to indemnify such Indemnified Party, or would otherwise result in liability of, or have an adverse impact upon, such Indemnifying Party. 

 

	5.	General Provisions 

  

	 	5.1	Force majeure. Any failure or omission by a party to timely perform any obligation under this Agreement shall not be deemed a breach of this Agreement to the
extent such failure or omission directly results from an event of force majeure. Force majeure is any cause which is not within the reasonable control of the parties, that they could not reasonably have planned for and against which they have not
protected themselves. Force majeure includes notably, without limitation, a third party strike, partial or complete interruption of work, lock-out, fire, rebellion, interventions by military or civil authorities, compliance with regulations or rules
of any governmental authority, and act of war (declared or not). 

  

	 	5.2	Notice. Any notice, demand, request, or other documents required or permitted to be given shall be given in hand to its recipient or be sent by registered mail,
major international delivery service, or by fax (and in which case said notice shall be confirmed by registered mail or major international delivery service the following business day) at the address indicated at the beginning of this Agreement or
at any other address which a party may indicate to the other party in accordance with this Agreement. Any such demand, request, or other document shall be deemed to be received by its recipient at the time of its delivery, if delivered in
person or the fifth (5th) day following its sending by registered mail, major international delivery service or fax. 

  
 7 

* Confidential treatment requested 

	 	5.3	Severability. Should any provision of this Agreement be deemed contrary to applicable law and/or unenforceable by any court of competent jurisdiction, such
provision shall be considered severed from this Agreement but all remaining provisions shall continue in full force. 

  

	 	5.4	Modification of the Agreement. This Agreement may be modified in whole or in part by common agreement between the parties and solely in writing.

  

	 	5.5	Titles. The titles are used for convenience only and do not affect the significance or the reach of the sections they refer to. 

 

	 	5.6	Non-waiver. Except for the provisions of this Agreement where the exercise of a right is accompanied with a specific delay, the silence of a party, its
negligence, or its lateness to exercise a right or recourse which is given to it or opened pursuant to this Agreement shall not be interpreted against such party as a waiver of its rights and recourses. 

 

	 	5.7	Cumulative and non-alternative. Rights mentioned are cumulative and not alternative. The waiver of the exercise of a right shall not be interpreted as a waiver
of any other right. 

  

	 	5.8	Independent parties. The parties acknowledge that they are acting as independent contractors and entrepreneurs and that nothing in this Agreement shall be
interpreted in such manner as to modify their respective positions. This Agreement does not in effect create a mandatory relation of associate, employee or a legal counsel acting in a dispute or disagreement between MCC and BioAmber.

  

	 	5.9	Arbitration. Any dispute or controversy which may arise between the parties out of or in connection with or in relation to this Agreement, or for breach thereof,
shall, unless settled amicably between the parties without undue delay, be settled by arbitration in New York, NY, in accordance with the rules of the International Chamber of Commerce (ICC). The award thereof shall be final and binding to both
parties. 

  

	 	5.10	Governing Law. This Agreement is made in, and shall be governed and controlled in all respects by the laws of the state of New York and all disputes, including
interpretation, enforceability, validity, and construction, shall be determined under the laws of the state of New York, without regard to any conflict of law provisions. 

 

	 	5.11	Entire Agreement. This Agreement expresses the complete and final agreement between the parties regarding the matters set forth herein and replaces all prior
contracts, agreements, commitments and understandings, oral or written between the parties bearing on the matters set forth herein. 

  
 8 

* Confidential treatment requested 

 IN WITNESS WHEREOF, THE PARTIES HAVE SIGNED THIS AGREEMENT AT THE PLACE AND AT THE DATE HEREINABOVE FIRST
MENTIONED. 
  

			
	BIOAMBER S.A.S.
		
	By:	 	/s/ Jean-François Huc
		 	Jean-François Huc, President
	
	MITSUBISHI CHEMICAL CORPORATION
		
	By:	 	/s/ S. Handa
		 	Signature
		
		 	 /s/ Shigeru Handa, General Manager

		 	Name and Title Sustainable Resources Business Development Dept.

 MITSUI & CO., LTD. intervenes to this agreement, hereby acknowledging and accepting the rights and
obligations accruing to it pursuant to Section 1.13. 
  

			
	MITSUI & CO., LTD.
		
	By:	 	 
		 	Signature
		
		 	 
		 	Name and Title

  
 9 

* Confidential treatment requested 

 Exhibit A 
 Product Specifications 
 Succinic Acid 99% 

 

					
	 Analysis
	  	Method	  	Specifications
	Appearance	  	—	  	[***]
	Particle size	  	—	  	[***]
	Color	  	—	  	[***]
	Water content	  	[***]	  	[***]
	Assay	  	[***]	  	[***]
	Melting Point	  	—	  	[***]
	Residue on Ignition	  	—	  	[***]
	Total Heavy Metals	  	—	  	[***]

 Storage: Store in unopened original packaging in dry place 

Packaging: 500kg big-bags / 800kg big-bags 

  
 10 

* Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]